NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Lantheus Holdings, Inc. (LNTH) Stock Analysis

Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LNTH

$100.24

−$0.15 (−0.15%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LNTH with… →

LNTH Key Statistics

As of Oct 21, 2026
Trading
Open
$100.28
Previous Close
$100.39
Day's Range
100.14–100.45
52-Week Range
50.16–111.86
Volume
1.41M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.06
Valuation
Market Cap
$6.55B
P/E Ratio
24.27
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.72
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.21
EPS (ttm)Profit attributable to each share over the last twelve months.
4.13
Financials (FY)
Revenue (FY)
$1.54B+0.50%
Net Income (FY)
$233.56M−25.25%
Profit marginThe share of revenue left as profit after all costs and taxes.
17.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.30M
1-Year Return
+73.73%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.38M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LNTH closed at $100.24, +73.73% over 1 year.

Lantheus Holdings, Inc. (LNTH) has a market capitalization of $6.55B.

In fiscal 2025, LNTH reported revenue of $1.54B.

LNTH Stock Return by Calendar Year

Lantheus Holdings, Inc. (LNTH) 10-year return: what $10,000 became

1 year
$10,000 $17,373
+73.73%
5 years
$10,000 $43,394
+333.94%
10 years
$10,000 $110,762
+1,007.62%

If you had invested $10,000 in Lantheus Holdings, Inc. (LNTH) 10 years ago, at the close on October 21, 2016, it would have been worth $110,762 at the close on October 21, 2026: +1,007.62% in total, +27.19% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+50.62%
2025−25.61%
2024+44.29%
2023+21.66%
2022+76.39%
2021+114.16%
2020−34.23%
2019+31.05%
2018−23.47%
2017+137.79%
2016 (partial year)+49.57%

As of October 21, 2026.

LNTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.54B$233.56M15.2%
2024$1.53B$312.44M20.4%
2023$1.30B$326.66M25.2%
2022$935.06M$28.07M3.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.54B$941.95M$315.56M$233.56M15.2%
2024$1.53B$988.29M$448.56M$312.44M20.4%
2023$1.30B$709.54M$364.64M$326.66M25.2%
2022$935.06M$581.70M$36.20M$28.07M3.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LNTH Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricLNTHDrug Manufacturers - Specialty & Generic medianvs median
P/E24.2720.3119% above
P/S ratio4.212.10100% above
Profit margin17.69%−8.14%25.8 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lantheus Holdings, Inc. (LNTH) carries a market capitalisation of $6.55B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 1,193.

LNTH last closed at $100.24 on October 21, 2026. That is −$0.15 (−0.15%) against the previous close. The 52-week range on file runs from $50.16 to $111.86. The latest close sits 99.86% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.54B. Against the prior fiscal year total of $1.53B, that is a change of +0.50%. Net income for the same year was $233.56M. That is −25.25% against the prior fiscal year. The reported profit margin is 17.69%. That is 25.8 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are 4.13.

Across the 4 fiscal years on file, revenue moves from $935.06M in 2022 to $1.54B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

LNTH trades at a trailing price-to-earnings ratio of 24.27. That is 19.47% above the Drug Manufacturers - Specialty & Generic median of 20.31. The forward P/E on file is 15.72. The price-to-sales ratio is 4.21. On price-to-sales that is 100.29% above the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +73.73%. Across 10 years the annualized return works out at +27.19%. The reported beta is −0.06. Annualized volatility over the trailing 10 years is 55.95%.

Growth & Income

No dividend is on file for LNTH.

The strongest complete calendar year on file is 2017 at +137.79%; the weakest is 2020 at −34.23%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the total return is +50.62%.

Peer Comparison

Lantheus Holdings, Inc. (LNTH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lantheus Holdings, Inc. LNTH $6.55B 24.3
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Lantheus Holdings, Inc. trades at a P/E of 24.3.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Visit website →